Autolus Therapeutics Secures 10-Year Critical Raw Material Supply for CAR-T Products

summarizeSummary

Autolus Therapeutics secured a 10-year agreement with AGC Biologics for the supply of critical lentiviral vector, essential for its CAR-T product manufacturing, with a minimum commitment of EUR 25 million over five years.

check_boxKey Events

• Secures Critical Supply Agreement

  Autolus Limited, a subsidiary, entered into a Master Service Agreement with AGC Biologics S.p.A for the manufacture and supply of lentiviral vector, a critical raw material for CAR-T products.

• Long-Term Operational Stability

  The agreement has a fixed term of ten years, replacing a prior arrangement and ensuring long-term supply chain stability for clinical and commercial CAR-T production.

• Significant Financial Commitment

  The company committed to purchasing a minimum of 14 batches of lentiviral vector in the first two years and a minimum value of EUR 25 million in products and services during the subsequent five-year period.

auto_awesomeAnalysis

Autolus Therapeutics has entered into a significant 10-year Master Service Agreement with AGC Biologics for the supply of lentiviral vector, a critical raw material for its CAR-T product manufacturing. This agreement replaces a prior arrangement, ensuring long-term supply chain stability for both clinical and commercial use of its CAR-T therapies, including obe-cel. The commitment to purchase a minimum of EUR 25 million in products and services over the subsequent five-year period underscores the strategic importance of this partnership for the company's operational continuity and growth, especially following its recent positive revenue and guidance announcements.